Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PDGFRA amp Imatinib malignant peripheral nerve sheath tumor sensitive detail...
Unknown unknown Dasatinib malignant peripheral nerve sheath tumor not applicable detail...
Unknown unknown Everolimus malignant peripheral nerve sheath tumor not applicable detail...
Unknown unknown Alisertib malignant peripheral nerve sheath tumor not applicable detail...
Unknown unknown Carfilzomib + Selinexor malignant peripheral nerve sheath tumor not applicable detail...
Unknown unknown Capmatinib malignant peripheral nerve sheath tumor not applicable detail...
ERBB2 D769Y Lapatinib malignant peripheral nerve sheath tumor predicted - sensitive detail...
Unknown unknown Ganetespib + Sirolimus malignant peripheral nerve sheath tumor no benefit detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02301039 Phase II Pembrolizumab A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas Active, not recruiting
NCT02372006 Phase Ib/II Afatinib Trial of Afatinib in Pediatric Tumours Active, not recruiting
NCT02584309 Phase II Dexrazoxane Doxorubicin + Olaratumab Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting
NCT02584647 Phase Ib/II Pexidartinib + Sirolimus Combination of PLX3397 and Sirolimus in Unresectable Sarcoma (Phase 1) and Malignant Peripheral Nerve Sheath Tumors (Phase 2) Recruiting
NCT02601209 Phase Ib/II Pazopanib Sapanisertib Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Active, not recruiting
NCT02639546 Phase Ib/II Cobimetinib Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (iMATRIXcobi) Active, not recruiting
NCT02700230 Phase I MV-NIS Vaccine Therapy in Treating Patients With Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery Recruiting
NCT02978859 Phase II MGCD516 MGCD516 in Advanced Liposarcoma and Other Soft Tissue Sarcomas Recruiting
NCT02986919 Phase II CPI-0610 Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors Withdrawn
NCT02987959 Phase II Sapanisertib Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas Active, not recruiting
NCT03009201 Phase I Doxorubicin + Ribociclib Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery Active, not recruiting
NCT03433183 Phase II Selumetinib + Sirolimus SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors Recruiting
NCT03872427 Phase II Telaglenastat Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, CB-839 HCl, Anti-Cancer Treatment, BeGIN Study Recruiting
NCT03880123 Phase I Ixazomib + Selinexor Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma Not yet recruiting
NCT04028063 Phase II Balstilimab + Doxorubicin + Zalifrelimab Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas Recruiting
NCT04465643 Phase I Ipilimumab + Nivolumab Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor Not yet recruiting